证券代码：300255 证券简称：常山药业 公告编号：2025-32 | | | | | | 单位：万元 | | --- | --- | --- | --- | --- | --- | | 项目 | 2024 | 年 | 12 31 月 | 日 | | | | | | | （未经审计） | | | 资产总额 | | | 55,944.09 | 50,987.47 | | | 银行贷款总额 | | | 16,344.10 | 11,182.45 | | | 流动负债总额 | | | 18,649.29 | 12,773.25 | | | 负债总额 | | | 23,986.89 | 18,949.21 | | | 或有事项涉及的总额（包括担保、抵押、 | | | | | | | 诉讼与仲裁事项） | | | | | | | 净资产 | | | 31,957.20 | 32,038.27 | | | 项目 | 2024 | 年 | 1 月—12 | 月 | | | | | | | | （未经审计） | | 营业收入 | | | 21,746.68 | | 6,348.74 | | 利润总额 | | | 85.24 ...

Core Viewpoint - Changshan Pharmaceutical announced that as of the date of the announcement, the company and its subsidiaries do not provide guarantees to entities outside the consolidated financial statements, nor do they have overdue guarantees, guarantees involved in litigation, or losses due to judgments against guarantees [1] Summary by Relevant Categories - **Company Guarantees** - The company confirmed that it does not provide guarantees to entities outside the consolidated financial statements [1] - There are no overdue guarantees reported by the company [1] - **Litigation and Losses** - The company stated that there are no guarantees involved in litigation [1] - There are no losses that the company needs to bear due to judgments against guarantees [1]

证券代码：300255 证券简称：常山药业 公告编号：2025-32 河北常山生化药业股份有限公司 关于为全资子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保情况概述 河北常山生化药业股份有限公司（以下简称"公司"）于 2025 年 5 月 19 日 召开的 2024 年度股东大会审议并通过《关于提供担保额度预计的议案》，同意公 司为全资子公司河北常山凯库得生物技术有限公司（以下简称"凯库得"）借款 融资提供不超过 3.6 亿元的担保额度，上述额度期限自股东大会审议通过之日起 至 2025 年度股东大会之日。具体内容详见公司刊登于巨潮资讯网的《关于提供 担保额度预计的公告》（公告编号：2025-14）。 本次担保事项在已经审议的年度担保额度范围内，无需再提交公司董事会或 股东大会审议。 三、被担保人基本情况 1．企业名称：河北常山凯库得生物技术有限公司 2．企业类型：有限责任公司 3．注册地址：中国（河北）自由贸易试验区正定片区正定县高新技术产业 开发区北区赵普大街 19 号 4．成立日期：2018 年 02 月 06 日 5 ...

Group 1 - The core point of the article is that the FDA has accelerated the approval of Wegovy (2.4 mg semaglutide) for treating moderate to severe liver fibrosis in adult patients with non-alcoholic steatohepatitis (NASH), leading to significant stock price increases for several pharmaceutical companies [1] Group 2 - Hanyu Pharmaceutical's stock rose over 10% following the news [1] - Companies such as Sunlight Novo and Jinkai Biotechnology saw stock increases of over 5% [1] - Novo Nordisk's stock rose over 6% in after-hours trading in the US market due to the FDA announcement [1]

Core Insights - The market for weight loss drugs is gaining significant attention, with companies like Silverno Pharmaceuticals and others experiencing substantial stock price increases [1][5][11] - Silverno Pharmaceuticals has seen a remarkable IPO performance, with a 5341.66 times oversubscription and a market capitalization exceeding HKD 26 billion [3] - The overall performance of weight loss-related stocks in both Hong Kong and A-share markets has been strong, with several companies reporting over 100% gains this year [5][8] Company Performance - Silverno Pharmaceuticals' core product, Isupaglutide α, has generated revenue of approximately CNY 38.14 million within four months of its launch in China [3] - Other companies like Pag Biopharma and Songli Pharmaceutical have also seen significant stock price increases, with Pag Biopharma rising 32.45% and Songli Pharmaceutical increasing by 13.72% [4][5] - In the A-share market, companies such as Borui Pharmaceutical and Changshan Pharmaceutical have reported gains of 280% and over 100%, respectively [8][10] Market Trends - The global obesity issue is driving the demand for weight loss drugs, positioning this sector as a "golden track" in the pharmaceutical industry [5] - Analysts predict that the GLP-1 drug market could exceed USD 150 billion by 2030, highlighting the potential for domestic oral weight loss drugs [11] - Companies with strong research and sales capabilities are expected to dominate the commercialization of weight loss drugs, with a focus on those with advanced R&D progress [11]

Group 1 - The chemical pharmaceutical sector increased by 2.34% on August 13, with Shouyao Holdings leading the gains [1] - The Shanghai Composite Index closed at 3683.46, up 0.48%, while the Shenzhen Component Index closed at 11551.36, up 1.76% [1] - Notable gainers in the chemical pharmaceutical sector included Shouyao Holdings, which rose by 19.99% to a closing price of 55.94, and Weichip Bio, which increased by 14.39% to 41.18 [1] Group 2 - The chemical pharmaceutical sector saw a net inflow of 342 million yuan from main funds, while retail investors contributed a net inflow of 426 million yuan [2] - Major stocks with significant net inflows included Heng Rui Pharmaceutical with 55.1 million yuan and Fu Xing Pharmaceutical with 23.4 million yuan [3] - Conversely, stocks like ST Sailong and ST Suwu experienced notable net outflows of 4.97% and 3.70%, respectively [2]

Group 1 - The core viewpoint of the articles highlights a significant rise in the innovative drug sector, driven by the establishment of a new pricing mechanism for newly launched drugs by the National Medical Insurance Administration [1][2] - The new pricing mechanism is expected to provide higher pricing flexibility, more efficient listing processes, and longer price stability periods for high-quality innovative drugs [1] - Companies in the innovative drug sector, such as Shouyao Holdings and Microchip Biotech, have seen substantial stock price increases, indicating positive market sentiment towards the sector [1] Group 2 - Since 2025, the government has repeatedly proposed policies to optimize drug procurement and support innovative drugs, indicating a favorable policy environment for the development of innovative drugs [2] - The investment strategy for the second half of 2025 suggests a high certainty of performance and valuation recovery in the healthcare industry, driven by external factors such as policy optimization and the rise of commercial health insurance [2] - The trend towards self-sufficiency and the reform of out-of-hospital marketing models are seen as more certain investment directions in the context of true innovation and internationalization in the pharmaceutical sector [2]

证券日报网讯常山药业（300255）8月11日在互动平台回答投资者提问时表示，截至8月8日，公司的股 东户数为55333户。 ...

证券日报网讯常山药业（300255）8月11日在互动平台回答投资者提问时表示，公司关于停牌描述是在 提示可能存在的停牌风险，公司未滥用停复牌制度。股票价格波动受多种因素影响，请充分了解二级市 场交易风险，审慎决策、理性投资，注意投资风险。 ...

证券之星消息，8月11日化学制药板块较上一交易日上涨1.29%，天宇股份领涨。当日上证指数报收于 3647.55，上涨0.34%。深证成指报收于11291.43，上涨1.46%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300702 | 天宇股份 | 29.77 | 14.50% | 26.66万 | | 7.87亿 | | 300436 | 广生堂 | 132.81 | 11.70% | 16.11万 | | 20.37亿 | | 603538 | 美诺华 | 28.68 | 10.01% | 51.47万 | | 14.26 乙 | | 002826 | 易明医药 | 22.81 | 9.98% | 19.74万 | | 4.38亿 | | 300255 | 常山药业 | 44.46 | 8.52% | 55.73万 | | 24.31亿 | | 300233 | 金城医药 | 19.14 | 7.65% | 57.97万 | | 10.9 ...